Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 23Classical hematology 16Myeloid 6Lymphoid 6Sarcoma 2Plasma cell 2Other solid neoplasm 1

Conditions

Multiple Myeloma 2Thrombocytopenia 1Recurrence 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
eltrombopag × Plasma cell × Clear all
NCT01286675 2019-03-01

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Completed
19 enrolled
Plasma cell

Multiple Myeloma

NCT01484314 2017-03-15

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Terminated
1 enrolled 1 chart
Classical hematologyPlasma cell

Multiple Myeloma, Recurrence, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡